Friday, April 15, 2011
ISTANBUL - Hürriyet Daily News
 'We want to continue investing in research and development in Turkey,' says Bert Tjeenk Willink of Boehringer Ingelheim, speaking in Istanbul on April 15, 2011. |
Boehringer Ingelheim, one of the world’s top pharmaceutical companies, said the recent price cuts imposed in Turkey have caused considerable financial loss, implying that it may exit the Turkish market.
“We don’t want to leave the market. We want to continue investing in research and development in Turkey,” said board member Bert Tjeenk Willink, speaking on the sidelines of a press conference in Istanbul on Friday.
The cuts imposed by the government have caused nearly a 10 percent decline in profitability, said Willink. “Our products are marketed as the cheapest price in all of Europe,” he told the Hürriyet Daily News & Economic Review.
The company is more hesitant than ever to invest further due to the unpredictability in the market, he said.
Willink said if the government wants more pharmaceutical companies to invest more in Turkey, then an urgent solution needed to be found.
The government has cut the price of original drugs by as much as 30 percent in total in December 2009 and November 2010, in an effort to cut health care spending to 14.96 billion Turkish Liras ($9.4 billion) in 2011 from 15.2 billion last year.
“They expect us to implement studies and invest in research and development in medicine, while they also expect us take care of the budget deficit of social security institutions,” Willink said. “We cannot afford to do that.”
The top executive said Boehringer products are being exported to Germany from Turkey. “We are pleased to sell discounted products here, as long as they don’t show up in other markets.”
According to new regulations imposed in December, the price cut in original drugs without a generic counterpart was determined at 32.5 percent. The figure is 20.5 percent for original drugs with generic alternatives.
“We don’t want to leave the market. We want to continue investing in research and development in Turkey,” said board member Bert Tjeenk Willink, speaking on the sidelines of a press conference in Istanbul on Friday.
The cuts imposed by the government have caused nearly a 10 percent decline in profitability, said Willink. “Our products are marketed as the cheapest price in all of Europe,” he told the Hürriyet Daily News & Economic Review.
The company is more hesitant than ever to invest further due to the unpredictability in the market, he said.
Willink said if the government wants more pharmaceutical companies to invest more in Turkey, then an urgent solution needed to be found.
The government has cut the price of original drugs by as much as 30 percent in total in December 2009 and November 2010, in an effort to cut health care spending to 14.96 billion Turkish Liras ($9.4 billion) in 2011 from 15.2 billion last year.
“They expect us to implement studies and invest in research and development in medicine, while they also expect us take care of the budget deficit of social security institutions,” Willink said. “We cannot afford to do that.”
The top executive said Boehringer products are being exported to Germany from Turkey. “We are pleased to sell discounted products here, as long as they don’t show up in other markets.”
According to new regulations imposed in December, the price cut in original drugs without a generic counterpart was determined at 32.5 percent. The figure is 20.5 percent for original drugs with generic alternatives.
Hiç yorum yok:
Yorum Gönder